Table 2. Immunological Recovery of... | American Society of Hematology

Table 2.

Immunological Recovery of Leukemia Patients Treated With Allo-BMT: Laboratory Findings at 3 and 12 Months After Transplantation

Patient	Age at BMT (yrs)	No. of Lymphocytes^*		No. of CD3⁺		No. of CD4⁺		No. of CD8⁺		No. of CD16⁺/56⁺ (CD3⁻)		No. of CD20⁺
Patient	Age at BMT (yrs)	3	12	3	12	3	12	3	12	3	12	3	12
I^†
UPN 272	11	1.05	1.12	0.89	0.71	0.09	0.15	0.81	0.55	0.03	0.10	0.12	0.29
UPN 273^‡	12	0.50	^2-153	0.20	—	0.13	—	0.11	—	0.30	—	0.03	—
UPN 279	10	1.05	2.76	0.15	1.35	0.05	0.97	0.13	0.41	0.38	0.25	0.39	1.0
II
UPN 298	7	0.68	5.25	0.51	4.25	0.03	0.79	0.48	3.30	0.20	0.47	0.007	0.21
UPN 301	2	1.88	3.07	1.39	2.18	0.76	1.35	0.76	0.68	0.47	0.06	0.17	0.65
UPN 329	2	1.34	^2-153	0.48	—	0.20	—	0.29	—	0.34	—	0.25	—
III
UPN 274	6	0.62	^2-153	0.56	—	0.09	—	0.47	—	0.11	—	0.006	—
UPN 275	11	1.87	2.96	1.46	2.16	0.19	0.59	1.25	1.6	0.32	0.47	0.08	0.62
UPN 276	14	1.36	2.93	1.09	2.08	0.39	0.85	0.71	1.29	0.20	0.41	0.09	0.70
UPN 285	10	1.03	1.96	0.73	0.80	0.22	0.53	0.58	0.55	0.27	0.31	0.02	0.80
UPN 291	7	1.72	3.50	1.31	2.21	0.24	0.98	1.07	1.23	0.21	0.25	0.21	0.95
UPN 296	15	0.83	0.43	0.37	0.23	0.12	0.15	0.21	0.09	0.18	0.09	0.22	0.23
Reference^2-155	2-4	3.7 (2.3-5.4)		2.1 (1.2-3.7)		1.3 (0.7-2.4)		0.7 (0.4-1.1)		0.5 (0.2-0.7)		0.8 (0.4-1.4)
	5-9	2.6 (1.7-3.5)		1.8 (1.0-2.6)		1.0 (0.6-1.5)		0.6 (0.3-1.0)		0.2 (0.1-0.5)		0.3 (0.2-0.7)
	10-14	2.4 (1.6-3.1)		1.6 (0.9-2.4)		0.9 (0.6-1.6)		0.5 (0.2-0.9)		0.3 (0.1-0.5)		0.3 (0.1-0.6)
	15-70	1.9 (1.3-3.0)		1.3 (0.8-1.9)		0.8 (0.5-1.2)		0.4 (0.3-0.8)		0.3 (0.1-0.6)		0.3 (0.1-0.6)

Patient	Age at BMT (yrs)	No. of Lymphocytes^*		No. of CD3⁺		No. of CD4⁺		No. of CD8⁺		No. of CD16⁺/56⁺ (CD3⁻)		No. of CD20⁺
Patient	Age at BMT (yrs)	3	12	3	12	3	12	3	12	3	12	3	12
I^†
UPN 272	11	1.05	1.12	0.89	0.71	0.09	0.15	0.81	0.55	0.03	0.10	0.12	0.29
UPN 273^‡	12	0.50	^2-153	0.20	—	0.13	—	0.11	—	0.30	—	0.03	—
UPN 279	10	1.05	2.76	0.15	1.35	0.05	0.97	0.13	0.41	0.38	0.25	0.39	1.0
II
UPN 298	7	0.68	5.25	0.51	4.25	0.03	0.79	0.48	3.30	0.20	0.47	0.007	0.21
UPN 301	2	1.88	3.07	1.39	2.18	0.76	1.35	0.76	0.68	0.47	0.06	0.17	0.65
UPN 329	2	1.34	^2-153	0.48	—	0.20	—	0.29	—	0.34	—	0.25	—
III
UPN 274	6	0.62	^2-153	0.56	—	0.09	—	0.47	—	0.11	—	0.006	—
UPN 275	11	1.87	2.96	1.46	2.16	0.19	0.59	1.25	1.6	0.32	0.47	0.08	0.62
UPN 276	14	1.36	2.93	1.09	2.08	0.39	0.85	0.71	1.29	0.20	0.41	0.09	0.70
UPN 285	10	1.03	1.96	0.73	0.80	0.22	0.53	0.58	0.55	0.27	0.31	0.02	0.80
UPN 291	7	1.72	3.50	1.31	2.21	0.24	0.98	1.07	1.23	0.21	0.25	0.21	0.95
UPN 296	15	0.83	0.43	0.37	0.23	0.12	0.15	0.21	0.09	0.18	0.09	0.22	0.23
Reference^2-155	2-4	3.7 (2.3-5.4)		2.1 (1.2-3.7)		1.3 (0.7-2.4)		0.7 (0.4-1.1)		0.5 (0.2-0.7)		0.8 (0.4-1.4)
	5-9	2.6 (1.7-3.5)		1.8 (1.0-2.6)		1.0 (0.6-1.5)		0.6 (0.3-1.0)		0.2 (0.1-0.5)		0.3 (0.2-0.7)
	10-14	2.4 (1.6-3.1)		1.6 (0.9-2.4)		0.9 (0.6-1.6)		0.5 (0.2-0.9)		0.3 (0.1-0.5)		0.3 (0.1-0.6)
	15-70	1.9 (1.3-3.0)		1.3 (0.8-1.9)		0.8 (0.5-1.2)		0.4 (0.3-0.8)		0.3 (0.1-0.6)		0.3 (0.1-0.6)

Absolute numbers: ×10³ cells/μL peripheral blood.

Transplantation groups as mentioned in Table 1.

Analysis at 68 days post-BMT; other time-points were not available.

Recipient died before second analysis at 1 year after transplantation (UPN 273, UPN 329, and UPN 274).

Age-matched reference values according to Comans-Bitter et al34; values are the median, with ranges from 5 to 95 percentiles in parentheses.